Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
暂无分享,去创建一个
S. Gettinger | M. Hurwitz | P. Hwu | M. Sznol | H. Kluger | V. Papadimitrakopoulou | D. Cho | C. Fanton | J. Zalevsky | M. Tagliaferri | B. Curti | N. Tannir | C. Haymaker | C. Bernatchez | S. Tykodi | A. Diab | S. Bentebibel | Ernesto Iacucci | A. Hannah | U. Hoch | A. Rizwan | S. Aung | Y. Liao | Sandra Aung